Genesis Launches Intermediate Accelerator

St. John’s-based startup hub Genesis has launched a new, intermediate-level accelerator to fill a gap between its Evolution program for early-stage companies and its Enterprise program for more advanced startups.

Dubbed Evolution+, the new accelerator eschews a cohort model in favour of rolling acceptance and graduation, with each company taking from one to six months to complete the program.

Continue Reading

Three Pitch Competitions Coming Soon

Three Atlantic Canadian startup support organizations will hold pitch competitions in the coming weeks: Halifax’s Volta, Moncton’s Venn Innovation and St. John's-based Genesis.

Startup incubator Volta will hold its quarterly pitch competition on August 11, with the application deadline of July 25 at 11:59 p.m.

Startup founders will have the chance to speak for three minutes in front of a panel

Continue Reading

Five Companies Pitch at Summer Institute

The University of New Brunswick held the virtual demo day Thursday for its Summer Institute accelerator, with five companies pitching.

Most startup accelerators teach lean methodology to innovation-driven businesses. The Summer Institute takes a different tack by seeking to back companies with positive social and environmental impacts.

Eight companies originally enrolled in the 13-week program,

Continue Reading

Survey Reveals Struggles of Black Female Founders

Black female entrepreneurs have particular difficulty accessing funding, although many are highly educated and their ventures are growing, a national survey has found.

The FoundHERs survey, conducted by market research firm Pitch Better Canada, analyzed the investment and financing options for Black female founders. The research found that 59 percent of Black women entrepreneurs hold

Continue Reading

IMV Preps for 2 Phase 2B Trials

IMV, the Dartmouth-based drug discovery company, is planning two Phase 2B trials in the coming months that it hopes will be key steps in bringing its lead compound DPX-Survivac to the market in a few years.

Though its shares have been languishing lately, the company has added key staff members after reporting good results on clinical trials for Survivac in December and is proceeding with further

Continue Reading